Dr. David Sallman, MD
Claim this profileMoffitt Cancer Center
Expert in Childhood Cancer
Studies Acute Myeloid Leukemia
17 reported clinical trials
23 drugs studied
Area of expertise
1Childhood Cancer
Global LeaderTP53 positive
FLT3 positive
CD123 positive
2Acute Myeloid Leukemia
TP53 positive
FLT3 positive
-7/del(7q) positive
Affiliated Hospitals
Clinical Trials David Sallman, MD is currently running
SX-682 + Decitabine
for Myelodysplastic Syndrome
This study will determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and recommended Phase 2 dose (RP2D) of SX-682 in the treatment of patients with Myelodysplastic Syndromes (MDS).
Recruiting1 award Phase 1
Canakinumab + Darbepoetin Alfa
for Myelodysplastic Syndrome
This study is a multi-institution, open-label, Phase 1b/2 clinical trial evaluating the toxicity and efficacy of canakinumab in combination with darbepoetin alfa in patients with lower-risk MDS who have failed prior treatment with an Erythropoietin Stimulating Agent (ESA)
Recruiting1 award Phase 1 & 26 criteria
More about David Sallman, MD
Clinical Trial Related4 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments David Sallman, MD has experience with
- Venetoclax
- Azacitidine
- SX-682
- PRGN-3006 T Cells
- Canakinumab Injection
- Darbepoetin Alfa
Breakdown of trials David Sallman, MD has run
Childhood Cancer
Acute Myeloid Leukemia
Granulocytic Leukemia
Myelodysplastic Syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David Sallman, MD specialize in?
David Sallman, MD focuses on Childhood Cancer and Acute Myeloid Leukemia. In particular, much of their work with Childhood Cancer has involved TP53 positive patients, or patients who are FLT3 positive.
Is David Sallman, MD currently recruiting for clinical trials?
Yes, David Sallman, MD is currently recruiting for 7 clinical trials in Tampa Florida. If you're interested in participating, you should apply.
Are there any treatments that David Sallman, MD has studied deeply?
Yes, David Sallman, MD has studied treatments such as Venetoclax, Azacitidine, SX-682.
What is the best way to schedule an appointment with David Sallman, MD?
Apply for one of the trials that David Sallman, MD is conducting.
What is the office address of David Sallman, MD?
The office of David Sallman, MD is located at: Moffitt Cancer Center, Tampa, Florida 33612 United States. This is the address for their practice at the Moffitt Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.